NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors - Implications for models of schizophrenia

Molecular Psychiatry

Volumn 7, Issue 8, 2002, Pages 837-844

  Kapur, S ^a   Seeman, P ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Dopamine; Glutamate; Ketamine; PCP; Schizophrenia; Serotonin

Indexed keywords

DOPAMINE 2 RECEPTOR; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE; RACLOPRIDE; SEROTONIN 2 RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ANIMALS; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); KETAMINE; NITROSO COMPOUNDS; PHENCYCLIDINE; RADIOLIGAND ASSAY; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SULFUR RADIOISOTOPES;

EID: 0036384325     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001093     Document Type: Article

References (59)

1. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 1999; 13: 358-371.
2. Seeman P, Kapur S. Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci U S A 2000; 97: 7673-7675.
3. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptors explain atypical antipsychotic action - a new hypothesis. Am J Psychiatry 2001; 158: 360-369.
4. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980; 20: 379-382.
5. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990; 13: 272-276.
6. Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia - therapeutic implications. Brain Res Brain Res Rev 2000; 31: 342-349.
7. Javitt DC. Glutamate receptors and schizophrenia: opportunities and caveats. Mol Psychiatry 1996; 1: 16-17.
8. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20: 201-225.
9. Swerdlow NR, Braff DL, Bakshi VP, Geyer MA. An animal model of sensorimotor gating deficits in schizophrenia predicts antipsychotic drug action. In: Csernansky JG (ed). Antipsychotics. Heidelberger Platz 3/W-1000 Berlin 33/Germany: Springer-Verlag: Berlin, 1996, pp 289-312.
10. Kari HP, Davidson PP, Kohl HH, Kochhar MM. Effects of ketamine on brain monoamine levels in rats. Res Commun Chem Pathol Pharmacol 1978; 20: 475-488.
11. Glisson SN, el-Etr AA, Bloor BC. The effect of ketamine upon norepinephrine and dopamine levels in rabbit brain parts. Naunyn Schmiedebergs Arch Pharmacol 1976; 295: 149-152.
12. Tsukada H, Harada N, Nishiyama S, Ohba H, Sato K, Fukumoto D et al. Ketamine decreased striatal [(11)C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis. Synapse 2000; 37: 95-103.
13. Nabeshima T, Ishikawa K, Yamaguchi K, Furukawa H, Kameyama T. Protection with phencyclidine against inactivation of 5-HT2 receptors by sulfhydryl-modifying reagents. Biochem Pharmacol 1988; 37: 3277-3283.
14. Rothman RB. PCP site 2: a high affinity MK-801-insensitive phencyclidine binding site. Neurotoxicol Teratol 1994; 16: 343-353.
15. Nishimura M, Sato K, Okada T, Yoshiya I, Schloss P, Shimada S et al. Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 1998; 88: 768-774.
16. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 1985; 117: 690-697.
17. Seeman P, Ulpian C, Wreggett KA, Wells JW. Dopamine receptor parameters detected by [3H]spiperone depend on tissue concentration: analysis and examples. J Neurochem 1984; 43: 221-235.
18. Liu IS, George SR, Seeman P. The human dopamine D2(Longer) receptor has a high-affinity state and inhibits adenylyl cyclase. Brain Res Mol Brain Res 2000; 77: 281-284.
19. Malmberg A, Mohell N. Characterization of [3H]quinpirole binding to human dopamine D2A and D3 receptors: effects of ions and guanine nucleotides. J Pharmacol Exp Ther 1995; 274: 790-797.
20. MacKenzie RG, VanLeeuwen D, Pugsley TA, Shih YH, Demattos S, Tang L et al. Characterization of the human dopamine D3 receptor expressed in transfected cell lines. Eur J Pharmacol 1994; 266: 79-85.
21. Watanabe M, George SR, Seeman P. Dependence of dopamine receptor conversion from agonist high- to low-affinity state on temperature and sodium ions. Biochem Pharmacol 1985; 34: 2459-2463
22. Lefkowitz RJ, Cotecchia S, Samama P, Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 1993; 14: 303-307.
23. Gardner B, Strange PG. Agonist action at D2(long) dopamine receptors: ligand binding and functional assays. Br J Pharmacol 1998; 124: 978-984.
24. Kapur S, Seeman P. Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor. Biol Psychiatry 2001; 49: 954-957.
25. Nishimura M, Sato K. Ketamine stereoselectively inhibits rat dopamine transporter. Neurosci Lett 1999; 274: 131-134.
26. Martin DC, Introna RP, Aronstam RS. Inhibition of neuronal 5-HT uptake by ketamine, but not halothane, involves disruption of substrate recognition by the transporter. Neurosci Lett 1990; 112: 99-103.
27. Martin DC, Adams RJ, Watkins CA. Inhibition of synaptosomal serotonin uptake by Ketalar. Res Commun Chem Pathol Pharmacol 1988; 62: 129-132.
28. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 1998; 88: 82-88.
29. Geisslinger G, Hering W, Thomann P, Knoll R, Kamp HD, Brune K. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J Anaesth 1993; 70: 666-671.
30. Domino EF, Zsigmond EK, Domino LE, Domino KE, Kothary SP, Domino SE. Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay. Anesth Analg 1982; 61: 87-92.
31. Idvall J, Ahlgren I, Aronsen KR, Stenberg P. Ketamine infusions: pharmacokinetics and clinical effects. Br J Anaesth 1979; 51: 1167-1173.
32. Shimoyama M, Shimoyama N, Gorman AL, Elliott KJ, Inturrisi CE. Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine. Pain 1999; 81: 85-93.
33. Tamminga CA. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 1998; 12: 21-36.
34. Carlsson M, Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? [Review]. Schizophr Bull 1990; 16: 425-432.
35. Hirota K, Okawa H, Appadu BL, Grandy DK, Devi LA, Lambert DG. Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology 1999; 90: 174-182.
36. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281: 1349-1352.
37. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-2927.
38. Swerdlow NR, Geyer MA. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 1998; 24: 285-301.
39. Swerdlow NR, Bakshi V, Waikar M, Taaid N, Geyer MA. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacol (Berl) 1998; 140: 75-80.
40. Verma A, Kulkarni SK. Modulation of MK-801 response by dopaminergic agents in mice. Psychopharmacology 1992; 107: 431-436.
41. Giannini AJ, Eighan MS, Loiselle RH, Giannini MC. Comparison of haloperidol and chlorpromazine in the treatment of phencyclidine psychosis. J Clin Pharmacol 1984; 24: 202-204.
42. Giannini AJ, Nageotte C, Loiselle RH, Malone DA, Price WA. Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity. J Toxicol Clin Toxicol 1984; 22: 573-579.
43. Giannini AJ, Price WA, Loiselle RH, Malone DW. Treatment of phenylcyclohexylpyrrolidine (PHP) psychosis with haloperidol. J Toxicol Clin Toxicol 1985; 23: 185-189.
44. Millan MJ, Brocco M, Gobert A, Joly F, Bervoets K, Rivet J et al. Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 1999; 11: 4419-4432.
45. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376.
46. Yamada S, Harano M, Annoh N, Nakamura K, Tanaka M. Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats. Biol Psychiatry 1999; 46: 832-838.
47. Carlsson ML. The selective 5-HT2a receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - implications for psychosis. J Neural Transm - Gen Sect 1995: 100: 225-237.
48. Arvanov VL, Wang RY, M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methylD-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 1998; 18: 197-209.
49. Wang RY, Liang X. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology 1998; 19: 74-85.
50. Bakshi VP, Geyer MA. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J Pharmacol Exp Ther 1997; 283: 666-674.
51. Announcement. Management decisions on priority pipeline products - MDL 100907. In: Vision Extra. 1999, pp 2-3.
52. Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Riviere ME, Papillon-Downey C. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am J Psychiatry 1999; 156: 419-425.
53. Toth E, Lajtha A. Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res 1986; 11: 393-400.
54. Kuribara H, Uchihashi Y. SCH 23390 equivalently, but YM-091512 differentially reduces the stimulant effects of methamphetamine, MK-801 and ketamine: assessment by discrete shuttle avoidance in mice. Jpn J Pharmacol 1993; 62: 111-114.
55. Jackson DM, Johansson C, Lindgren LM, Bengtsson A. Dopamine receptor antagonists block amphetamine and phencyclidineinduced motor stimulation in rats. Pharmacol Biochem Behav 1994; 48: 465-471.
56. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacol (Berl) 1999; 145: 193-204.
57. Nabeshima T, Ishikawa K, Yamaguchi K, Furukawa H, Kameyama T. Phencyclidine-induced head-twitch responses as 5-HT2 receptor-mediated behavior in rats. Neurosci Lett 1987; 76: 335-338.
58. Varty GB, Bakshi VP, Geyer MA. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpineinduced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 1999; 20: 311-321.
59. Wang RY, Liang X. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology 1998; 19: 74-85.